Bispecific antibody platforms for cancer immunotherapy

Crit Rev Oncol Hematol. 2014 Dec;92(3):153-65. doi: 10.1016/j.critrevonc.2014.08.003. Epub 2014 Aug 20.


Over the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novel bispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinical studies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that were encountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward.

Keywords: Anti-cancer therapy; Bi-specific antibodies; Dual specific retargeting; Immune effector cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Bispecific / pharmacology
  • Antibodies, Bispecific / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Drug Evaluation, Preclinical
  • Humans
  • Immunotherapy
  • Lymphocyte Subsets / drug effects
  • Lymphocyte Subsets / immunology
  • Molecular Targeted Therapy
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Single-Chain Antibodies / pharmacology
  • Single-Chain Antibodies / therapeutic use


  • Antibodies, Bispecific
  • Antineoplastic Agents
  • Single-Chain Antibodies